Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib maintenance after adjuvant chemotherapy in gastric cancer with positive peritoneal exfoliative cancer cells
ChiCTR-IPR-15006994Phase 4Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Sep 2015
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in gastric cancer (GC) (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Disease-free survival. Planned start Sep 2015; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR-IPR-15006994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006994.